Compare NABL & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NABL | GLUE |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | NABL | GLUE |
|---|---|---|
| Price | $7.18 | $24.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $9.31 | ★ $27.00 |
| AVG Volume (30 Days) | 814.4K | ★ 2.4M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $497,665,000.00 | $181,538,000.00 |
| Revenue This Year | $11.18 | $84.02 |
| Revenue Next Year | $8.73 | N/A |
| P/E Ratio | ★ N/A | $100.27 |
| Revenue Growth | 8.65 | ★ 1112.27 |
| 52 Week Low | $6.07 | $3.50 |
| 52 Week High | $10.41 | $25.77 |
| Indicator | NABL | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 72.34 |
| Support Level | $7.07 | $13.69 |
| Resistance Level | $7.48 | $25.77 |
| Average True Range (ATR) | 0.21 | 1.51 |
| MACD | -0.02 | 0.84 |
| Stochastic Oscillator | 22.22 | 89.74 |
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.